PL376224A1 - Pochodne imidazolu oraz ich zastosowanie jako obwodowo selektywnych inhibitorów beta-hydrolazy dopaminowej - Google Patents

Pochodne imidazolu oraz ich zastosowanie jako obwodowo selektywnych inhibitorów beta-hydrolazy dopaminowej

Info

Publication number
PL376224A1
PL376224A1 PL03376224A PL37622403A PL376224A1 PL 376224 A1 PL376224 A1 PL 376224A1 PL 03376224 A PL03376224 A PL 03376224A PL 37622403 A PL37622403 A PL 37622403A PL 376224 A1 PL376224 A1 PL 376224A1
Authority
PL
Poland
Prior art keywords
hydroxylase
dopamine
peripherally
beta
selective inhibitors
Prior art date
Application number
PL03376224A
Other languages
English (en)
Other versions
PL218537B1 (pl
Inventor
David Alexander Learmonth
Da Silva Patricio Manuel Vieira Araujo Soares
Alexander Beliaev
Original Assignee
Portela & C.A, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0223719A external-priority patent/GB2393958A/en
Application filed by Portela & C.A, S.A. filed Critical Portela & C.A, S.A.
Publication of PL376224A1 publication Critical patent/PL376224A1/pl
Publication of PL218537B1 publication Critical patent/PL218537B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Opisano związki o wzorze (I) i sposób ich wytwarzania, gdzie X oznacza CH<sub>2</sub>, O lub S, a n oznacza liczbę 1, 2 lub 3, pod warunkiem, że jeśli X oznacza CH<sub>2</sub>, to n nie oznacza liczby 1. Związki te mają potencjalnie wartościowe właściwości farmaceutyczne do leczenia chorób sercowo-naczyniowych takich, jak nadciśnienie i chroniczna niewydolność serca.
PL376224A 2002-10-11 2003-10-10 Pochodna chromanylu, tiochromanylu lub naftalenylu, sposób wytwarzania jej pojedynczych enancjomerów (R) i (S) albo mieszanin tych enancjomerów i farmaceutycznie dopuszczalnych soli i związków pośrednich, zawierająca ją kompozycja oraz zastosowanie tej pochodnej PL218537B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0223719A GB2393958A (en) 2002-10-11 2002-10-11 Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase
GB0224306A GB2394223B (en) 2002-10-11 2002-10-18 Peripherally-selective inhibitors of dopamine-beta-hydroxylase and method of their preparation

Publications (2)

Publication Number Publication Date
PL376224A1 true PL376224A1 (pl) 2005-12-27
PL218537B1 PL218537B1 (pl) 2014-12-31

Family

ID=32031889

Family Applications (1)

Application Number Title Priority Date Filing Date
PL376224A PL218537B1 (pl) 2002-10-11 2003-10-10 Pochodna chromanylu, tiochromanylu lub naftalenylu, sposób wytwarzania jej pojedynczych enancjomerów (R) i (S) albo mieszanin tych enancjomerów i farmaceutycznie dopuszczalnych soli i związków pośrednich, zawierająca ją kompozycja oraz zastosowanie tej pochodnej

Country Status (13)

Country Link
US (2) US7125904B2 (pl)
EP (5) EP1914233B8 (pl)
JP (1) JP4620464B2 (pl)
KR (1) KR101155159B1 (pl)
AU (1) AU2003271945B2 (pl)
BR (1) BRPI0315143B8 (pl)
CA (1) CA2501819C (pl)
GB (2) GB2432159B (pl)
MX (1) MXPA05003847A (pl)
PL (1) PL218537B1 (pl)
PT (1) PT103029B (pl)
RU (1) RU2332416C2 (pl)
WO (1) WO2004033447A1 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600709D0 (en) * 2006-01-13 2006-02-22 Portela & Ca Sa Drug combinations
GB0610804D0 (en) * 2006-05-31 2006-07-12 Portela & Ca Sa New crystal forms
JP5372771B2 (ja) * 2006-12-12 2013-12-18 ビアル−ポルテア アンド シー．エイ．， エス．エイ． プロセス
GB0700635D0 (en) * 2007-01-12 2007-02-21 Portela & Ca Sa Therapy
GB0701965D0 (en) * 2007-02-01 2007-03-14 Portela & Ca Sa Process
EP2121668A2 (en) * 2007-02-01 2009-11-25 BIAL - Portela & Ca., S.A. 6,8-dichlorchroman-3-yl-1,3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders
GB0701966D0 (en) * 2007-02-01 2007-03-14 Portela & Ca Sa Process
AU2008229203B2 (en) * 2007-03-16 2014-05-29 Emory University Methods and compositions for treatment of drug addiction
GB0708818D0 (en) * 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
GB0709695D0 (en) * 2007-05-21 2007-06-27 Portela & Ca Sa Process
TW200927740A (en) * 2007-11-13 2009-07-01 Bial Portela & Ca Sa Process
JP2011506315A (ja) 2007-12-05 2011-03-03 バイアル−ポルテラ アンド シーエー，エス．エー． 新たな塩、及び結晶形
AR070841A1 (es) * 2008-03-13 2010-05-05 Bial Portela & Ca Sa Proceso de hidrogenacion catalitica asimetrica
US8313984B2 (en) * 2008-03-19 2012-11-20 Ati Technologies Ulc Die substrate with reinforcement structure
EP2297042B1 (en) 2008-03-19 2013-07-10 Bial-Portela & CA, S.A. Catalytic asymmetric hydrogenation
AR071632A1 (es) * 2008-05-06 2010-06-30 Bial Portela & Ca Sa Proceso catalitico para hidrogenacion asimetrica en la sintesis de inhibidores de la dopamina-beta-hidroxilasa"
KR20220150995A (ko) * 2008-11-10 2022-11-11 알닐람 파마슈티칼스 인코포레이티드 치료제 운반용 신규 지질 및 조성물
JP5574480B2 (ja) * 2009-03-12 2014-08-20 国立大学法人高知大学 アミノ基含有アセトン誘導体、及びそれを用いた炭素−炭素結合形成方法
CN102207678B (zh) * 2010-01-25 2015-05-20 罗门哈斯电子材料有限公司 包含含氮化合物的光致抗蚀剂
RU2604734C2 (ru) * 2010-12-22 2016-12-10 БИАЛ-ПОРТЕЛА энд КА., С.А. Кристаллическая форма и способ ее очистки
WO2013002660A2 (en) 2011-06-29 2013-01-03 BIAL - PORTELA & Cª, S.A. Process
EP3971178A1 (en) 2012-03-07 2022-03-23 The McLean Hospital Corporation Aminoquinoline derivatives and uses thereof
KR102259938B1 (ko) * 2012-11-14 2021-06-03 바이알 - 포르텔라 앤드 씨에이 에스에이 폐동맥 고혈압 및 폐 손상의 치료에 이용하기 위한 1,3-디히드로이미다졸-2-티온 유도체
GB201316410D0 (en) 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein
JOP20190050A1 (ar) * 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
CN111479812A (zh) 2017-12-04 2020-07-31 巴尔-波特拉及康邦亚股份有限公司 多巴胺-b-羟化酶抑制剂
GB201810395D0 (en) 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
WO2020123699A1 (en) * 2018-12-11 2020-06-18 The Trustees Of Columbia University In The City Of New York Compounds and compositions that cause mycn and/or cmyc degradation and methods of use thereof
GB201908044D0 (en) 2019-06-05 2019-07-17 Bial Portela & Ca Sa Dopamine-B-Hydroxylase inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR862239B (en) 1985-09-03 1986-12-31 Ciba Geigy Ag 3-amino-dihydro-(1)-benzopyrans and benzothiopyrans
JPS63286408A (ja) * 1987-04-30 1988-11-24 ワツカー−ケミー・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 極性化合物の重合法
FR2619113B2 (fr) 1987-05-26 1991-06-28 Exsymol Sa Nouveaux produits de condensation de silanols, leurs preparation et application
US4868210A (en) * 1988-03-30 1989-09-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
US5013854A (en) 1989-02-02 1991-05-07 Eli Lilly And Company Process for preparing acid halides
SE8904361D0 (sv) 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
AU639301B2 (en) * 1990-01-11 1993-07-22 Pharmacia & Upjohn Company New centrally acting 6,7,8,9-tetrahydro-3h-benz(e)indole heterocyclics
IT1241988B (it) 1990-06-15 1994-02-02 Sigma Tau Ind Farmaceuti 2- amminotetraline-6, 7-sostituite attive come immunomodulanti e composizioni farmaceutiche che le contengono
DD297249A5 (de) 1990-08-07 1992-01-02 Veb Mineralwollewerk Flechtingen Bereich F/E Mineralwolle,De Verfahren zur automatischen ueberwachung des aushaertegrades an materialbahnen
US5438150A (en) * 1994-04-26 1995-08-01 Syntex (U.S.A.) Inc. Process for making 1-benzocycloalkyl-1,3-dihydroimidazole-2-thione derivatives
RU2145321C1 (ru) * 1994-04-26 2000-02-10 Синтекс (Ю.Эс.Эй) Инк. Производные бензоциклоалкилазолотиона
US5538988A (en) * 1994-04-26 1996-07-23 Martinez; Gregory R. Benzocycloalkylazolethione derivatives
GB2290790A (en) 1994-06-30 1996-01-10 Merck & Co Inc Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
IT1271009B (it) 1994-09-13 1997-05-26 Zambon Spa Derivati del benzopirano e del benzotiopirano attivi sul sistema cardiovascolare
JPH08259572A (ja) * 1995-01-24 1996-10-08 Toyama Chem Co Ltd 新規なセファロスポリン誘導体またはその塩
IT1278045B1 (it) 1995-03-09 1997-11-17 Sigma Tau Ind Farmaceuti Uso di 2-amminotetraline-6,7-sostituite per la preparazione di composizioni farmaceutiche atte al trattamento dello shock, e di
IT1294931B1 (it) 1997-09-22 1999-04-23 Sigma Tau Ind Farmaceuti Derivati della 2-amminotetralina procedimento per la loro preparazione e composizioni farmaceutiche che li contengono, attive nella
SE9801726D0 (sv) 1998-05-15 1998-05-15 Astra Ab New process
CA2338328A1 (en) 1998-07-21 2000-02-03 Thomas Jefferson University Small molecule inhibitors of bcl-2 proteins
ES2224483T3 (es) 1999-04-19 2005-03-01 General Electric Company Aminas terciarias bis-sililicas.
US20010039343A1 (en) 2000-01-28 2001-11-08 Mulvihill Mark Joseph Process to intermediates for biologically active compounds
DZ3415A1 (fr) * 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
US20020094316A1 (en) 2001-01-09 2002-07-18 Shuang Liu Polypodal chelants for metallopharmaceuticals

Also Published As

Publication number Publication date
EP1908759B1 (en) 2012-03-21
BRPI0315143B8 (pt) 2021-05-25
GB0702982D0 (en) 2007-03-28
EP1914233B1 (en) 2011-03-02
EP1408038A3 (en) 2004-04-21
PT103029A (pt) 2004-05-31
GB2432159A (en) 2007-05-16
EP1911757A2 (en) 2008-04-16
US7259271B2 (en) 2007-08-21
PL218537B1 (pl) 2014-12-31
EP1908760B1 (en) 2011-04-13
GB2432158B (en) 2007-06-27
EP1408038A2 (en) 2004-04-14
PT103029B (pt) 2005-05-31
US20040142996A1 (en) 2004-07-22
EP1908759A3 (en) 2008-04-16
EP1408038B1 (en) 2008-08-06
US20070015730A1 (en) 2007-01-18
WO2004033447A1 (en) 2004-04-22
GB2432159B (en) 2007-06-27
AU2003271945A1 (en) 2004-05-04
GB0702981D0 (en) 2007-03-28
JP2006507261A (ja) 2006-03-02
EP1911757B1 (en) 2011-03-02
EP1908760A1 (en) 2008-04-09
EP1914233B8 (en) 2011-04-13
KR20050057647A (ko) 2005-06-16
BR0315143A (pt) 2005-08-16
BRPI0315143B1 (pt) 2017-02-14
EP1908759A2 (en) 2008-04-09
RU2005114021A (ru) 2005-11-10
EP1911757B8 (en) 2011-05-25
CA2501819A1 (en) 2004-04-22
US7125904B2 (en) 2006-10-24
GB2432158A (en) 2007-05-16
RU2332416C2 (ru) 2008-08-27
AU2003271945B2 (en) 2009-12-17
KR101155159B1 (ko) 2012-06-11
CA2501819C (en) 2012-09-04
EP1911757A3 (en) 2008-05-28
JP4620464B2 (ja) 2011-01-26
MXPA05003847A (es) 2005-06-22
EP1914233A1 (en) 2008-04-23

Similar Documents

Publication Publication Date Title
PL376224A1 (pl) Pochodne imidazolu oraz ich zastosowanie jako obwodowo selektywnych inhibitorów beta-hydrolazy dopaminowej
DE60322267D1 (de) Chinolinderivate als glucokinase liganden
BR0310106A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto e método para o tratamento de um sujeito em sofrimento de uma condição ou doença patalógica
SE0200920D0 (sv) Novel compounds
IS7965A (is) Þíenópýrimidíndíón og notkun þeirra í breytingu ásjálfsnæmissjúkdómi
EA200600122A1 (ru) Производные пиримидина для лечения патологического роста клеток
WO2006048330A8 (en) 11βετα-hsd1 inhibitors
MXPA03011681A (es) Uso de inhibidores de epoxido hidrolasa soluble, para tratar enfermedades relacionadas con la enfermedad cardiovascular.
DE50009736D1 (de) Biphenylderivate, ihre herstellung und ihre verwendung als mtp-inhibitor
NO20005461D0 (no) Nye fettsyreanaloger for behandling av overvekt, høyt blodtrykk og fettlever
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
HUP0303637A2 (hu) Nitrogéntartalmú spirotriciklusos-származékok, eljárás előállításukra, valamint ezeket tartalmazó foszfodiészteráz-7-inhibitorként alkalmazható gyógyszerkészítmények
CY1109906T1 (el) Παραγωγα c3-kyano εποθιλονης
GB0112348D0 (en) Compounds
SE0302760D0 (sv) New compounds
CA2589850A1 (en) Amide prodrug of gemcitabine, compositions and use thereof
TW200510333A (en) Benzimidazole compounds
DK1727817T3 (da) Azabicyclooctan-3-onderivativer og anvendelse heraf
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
SE0203070D0 (en) Novel compounds
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments
WO2008106125A3 (en) Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists
BG106847A (en) Substituted piperazine derivatives as mtp inhibitors
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
TNSN06233A1 (en) 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments